Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Panel Backs Draft ARI Prevention Guidelines, Due Out November
September 5, 2025
- Japan Kicks Off Debate on Medical Data Use Framework, Eyes 2027 Legislation
September 4, 2025
- MHLW Seeks Sponsor for Drug Loss Product Trifarotene
September 4, 2025
- Japan Govt Council Gathers Views to Shape National MCM Strategy
September 4, 2025
- Japan Panel Supports Plan to Prioritize MCM Development by Need and Feasibility
September 4, 2025
- Generics Surge in FY2024 on New Out-of-Pocket Rule for Long-listed Drugs
September 3, 2025
- Pharma Groups Press Pricing Reform at First Public-Private WG Meeting
September 2, 2025
- Japan Panel Clears Izervay, Nexletol for Approval; Eylea Biosimilars Edge Ahead Too
September 1, 2025
- METI Proposes “Bold Investment” Tax Breaks in FY2026 Request
September 1, 2025
- Japan Panel Green Lights Nonprescription Switch of Morning-After Pill
September 1, 2025
- MHLW Orders Label Revision for Elevidys to Add Acute Hepatic Failure
September 1, 2025
- Japan Doles Out Orphan Tags to Ultragenyx’s GTX-102 and Lots More
September 1, 2025
- Japan Expects COVID Vaccine Supply of 9 Million Doses in 2025-26
September 1, 2025
- Japan Govt to Spearhead Development of Ultra-Orphan and Infectious Disease Drugs: FY2026 MHLW Budget Request
August 29, 2025
- Japan Moves Toward OTC Morning-After Pill Sales Without Age Limit or Parental Consent
August 29, 2025
- Diagnostics Industry Urges Mechanism to Reflect Rising Costs in Reimbursement
August 29, 2025
- Japan to Expand List of “Stable Supply Medicines” to 759 APIs, Adding Vaccines and Blood Products
August 28, 2025
- Japan to Apply Drug Pricing Rules for Krystal Gene Therapy: Chuikyo
August 28, 2025
- MHLW's FY2026 Budget Bid Prioritizes Innovation, Stockpiles, Ultra-Orphan Support
August 27, 2025
- MHLW Pharma Bureau Seeks FY2026 Budget to Bolster PMDA and Speed Up SaMD Reviews
August 27, 2025
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…